Baseline characteristics.

1<p>Categorical parameters are described by absolute number and percentage of patients in given category; continuous variables are described by median (5^th; 95^th percentile).</p>2<p>Overall statistical significance of differences among groups is based on Mann-Whitney test for continuous variables and ML chi-square test for categorical variables,</p>3<p>Creatinine clearance was estimated according to MDRD formula;</p>*<p>statistically significant.</p><p>BMI – Body mass index, TIA – Transitory ischemic attack, EF LV – Ejection fraction of left ventricle, PA systolic – Pulmonary artery systolic pressure, AVA – Aortic valve area.</p

ROC analysis for prediction of endpoints in patients treated with TAVI.

<p>ROC analysis for prediction of endpoints in patients treated with TAVI.</p

Risk assessment plot of the performance comparison between reference EuroSCORE model and new EuroSCORE+MDA model for combined safety endpoint at 30 days in TAVI+SAVR group (N = 42).

<p>Prevalence – occurrence of endpoint in given group.</p

Evaluation of additional benefit of biomarkers to clinical model (EuroSCORE) by net reclassification improvement (NRI) and the integrated discrimination improvement (IDI) for prediction of combined safety endpoint at 30 days and combined endpoint (0–365 days) in groups of patients treated by TAVI and by SAVR and TAVI.

<p>Evaluation of additional benefit of biomarkers to clinical model (EuroSCORE) by net reclassification improvement (NRI) and the integrated discrimination improvement (IDI) for prediction of combined safety endpoint at 30 days and combined endpoint (0–365 days) in groups of patients treated by TAVI and by SAVR and TAVI.</p

Risk assessment plot of the performance comparison between reference EuroSCORE model and new EuroSCORE+MDA model for combined safety endpoint at 30 days in TAVI group (N = 29).

<p>Risk assessment plot of the performance comparison between reference EuroSCORE model and new EuroSCORE+MDA model for combined safety endpoint at 30 days in TAVI group (N = 29).</p

Occurrence of endpoints in SAVR and TAVI groups.

1<p>Categorical parameters are described by absolute number and percentage of patients in given category.</p>2<p>Overall statistical significance of differences among groups is based on ML chi-square test;</p>*<p>statistically significant.</p